Latest News and Press Releases

PALO ALTO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and...

PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and...

ACEA Therapeutics (“ACEA”) will serve as exclusive territories distributor in Greater China, including mainland China, Taiwan, Hong Kong and Macau, with potential minimum purchase commitment for...

Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. (Nasdaq: DECA) (“SPAC”) announce signing of...

The ceremony will be held in celebration of Scilex’s launch of GLOPERBA®, an innovative non-opioid product and the first oral liquid medicine for prophylactic treatment of painful gout flares. PALO...

ZTlido® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year.ZTlido® net sales for the quarter ended June 2024 grew in the range of 28% to 42%,...

PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and...

The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for...

Up to 60% of patients with migraine do not sufficiently respond to triptans.Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of...

PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and...